Alnylam Pharmaceuticals Stock Performance
| ALNY Stock | USD 481.59 5.68 1.19% |
On a scale of 0 to 100, Alnylam Pharmaceuticals holds a performance score of 14. The firm shows a Beta (market volatility) of -0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Alnylam Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Alnylam Pharmaceuticals is likely to outperform the market. Please check Alnylam Pharmaceuticals' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Alnylam Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.19 | Five Day Return 2.75 | Year To Date Return 106.14 | Ten Year Return 446.33 | All Time Return 7.9 K |
1 | Acquisition by Kevin Fitzgerald of 2851 shares of Alnylam Pharmaceuticals subject to Rule 16b-3 | 08/15/2025 |
2 | Disposition of 144 shares by Tanguler Tolga of Alnylam Pharmaceuticals at 452.49 subject to Rule 16b-3 | 08/29/2025 |
3 | The top biopharma conferences in 2026 | 10/01/2025 |
4 | Alnylam Pharmaceuticals CEO Sells 4,034,094.20 in Stock | 10/06/2025 |
5 | Truist Financial Corp Purchases 383 Shares of Alnylam Pharmaceuticals, Inc. ALNY | 10/13/2025 |
6 | What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals | 10/15/2025 |
7 | Alnylam price target raised by 76 at Truist, heres why ALNY | 10/17/2025 |
8 | Why Alnylam Might be Well Poised for a Surge | 10/20/2025 |
9 | NVOs Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients | 10/21/2025 |
10 | Alnylam price target raised by 125 at Cantor Fitzgerald, heres why ALNY | 10/22/2025 |
11 | Ad hoc announcement pursuant to Art. 53 LR Roche continues strong sales growth momentum of 7 percent in the first nine months of 2025 full-year earnings outlook... | 10/23/2025 |
12 | Intellia pauses gene therapy trials after patient suffers liver injury, shares slide | 10/27/2025 |
13 | Zoetis Gears Up to Report Q3 Earnings Heres What to Expect | 10/29/2025 |
| Begin Period Cash Flow | 814.9 M | |
| Total Cashflows From Investing Activities | -116.8 M |
Alnylam Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 40,180 in Alnylam Pharmaceuticals on August 1, 2025 and sell it today you would earn a total of 7,979 from holding Alnylam Pharmaceuticals or generate 19.86% return on investment over 90 days. Alnylam Pharmaceuticals is currently generating 0.3014% in daily expected returns and assumes 1.663% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Alnylam, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alnylam Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alnylam Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alnylam Pharmaceuticals, and traders can use it to determine the average amount a Alnylam Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1813
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALNY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.66 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.3 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Alnylam Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alnylam Pharmaceuticals by adding it to a well-diversified portfolio.
Alnylam Pharmaceuticals Fundamentals Growth
Alnylam Stock prices reflect investors' perceptions of the future prospects and financial health of Alnylam Pharmaceuticals, and Alnylam Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alnylam Stock performance.
| Return On Equity | -2.58 | ||||
| Return On Asset | -0.0263 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 58.87 B | ||||
| Shares Outstanding | 131.08 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 241.13 X | ||||
| Price To Sales | 25.34 X | ||||
| Revenue | 2.25 B | ||||
| Gross Profit | 2.06 B | ||||
| EBITDA | (178.85 M) | ||||
| Net Income | (278.16 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 1.3 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 1.91 X | ||||
| Cash Flow From Operations | (8.31 M) | ||||
| Earnings Per Share | (2.47) X | ||||
| Market Capitalization | 62.38 B | ||||
| Total Asset | 4.24 B | ||||
| Retained Earnings | (7.29 B) | ||||
| Working Capital | 2.11 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
About Alnylam Pharmaceuticals Performance
Evaluating Alnylam Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Alnylam Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alnylam Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 88.62 | 84.19 | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (4.15) | (3.94) |
Things to note about Alnylam Pharmaceuticals performance evaluation
Checking the ongoing alerts about Alnylam Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alnylam Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.25 B. Net Loss for the year was (278.16 M) with profit before overhead, payroll, taxes, and interest of 2.06 B. | |
| Alnylam Pharmaceuticals currently holds about 2.27 B in cash with (8.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.41. | |
| Alnylam Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thefly.com: Agilent names new CFO A |
- Analyzing Alnylam Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alnylam Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Alnylam Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alnylam Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alnylam Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alnylam Pharmaceuticals' stock. These opinions can provide insight into Alnylam Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.